Hospital days during the different phases of therapy
| Phase . | MTX . | SDI, mean . | No.* . | DDI, mean . | No.* . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| PO, mean . | No.* . | IV, mean . | No.* . | P . | ||||||
| Induction | 9.21 | 1035 | 9.33 | 1037 | .67 | 9.35 | 1034 | 9.18 | 1038 | .53 |
| Consolidation | 2.11 | 1030 | 2.09 | 1036 | .91 | 2.19 | 1030 | 2.01 | 1036 | .39 |
| IM-1 | 1.22 | 1020 | 0.98 | 1013 | .15 | 1.14 | 1019 | 1.06 | 1014 | .61 |
| DI-1 | 4.56 | 1010 | 2.70 | 999 | < .0001 | 3.80 | 1011 | 3.47 | 998 | .19 |
| IM-2 | 0.98 | 988 | 0.97 | 976 | .96 | 0.87 | 991 | 1.08 | 973 | .11 |
| DI-2 | 4.80 | 482 | 2.74 | 468 | < .0001 | — | — | 3.79 | 950 | — |
| Maintenance course 1 | 1.19 | 954 | 1.09 | 963 | .48 | 1.17 | 978 | 1.11 | 939 | .69 |
| Phase . | MTX . | SDI, mean . | No.* . | DDI, mean . | No.* . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| PO, mean . | No.* . | IV, mean . | No.* . | P . | ||||||
| Induction | 9.21 | 1035 | 9.33 | 1037 | .67 | 9.35 | 1034 | 9.18 | 1038 | .53 |
| Consolidation | 2.11 | 1030 | 2.09 | 1036 | .91 | 2.19 | 1030 | 2.01 | 1036 | .39 |
| IM-1 | 1.22 | 1020 | 0.98 | 1013 | .15 | 1.14 | 1019 | 1.06 | 1014 | .61 |
| DI-1 | 4.56 | 1010 | 2.70 | 999 | < .0001 | 3.80 | 1011 | 3.47 | 998 | .19 |
| IM-2 | 0.98 | 988 | 0.97 | 976 | .96 | 0.87 | 991 | 1.08 | 973 | .11 |
| DI-2 | 4.80 | 482 | 2.74 | 468 | < .0001 | — | — | 3.79 | 950 | — |
| Maintenance course 1 | 1.19 | 954 | 1.09 | 963 | .48 | 1.17 | 978 | 1.11 | 939 | .69 |
MTX indicates methotrexate in interim maintenance; PO, oral; SDI, single delayed intensification; DDI, double delayed intensification; IM, interim maintenance phase; and DI, delayed intensification phase.
Number of patients with available data about hospital days.